ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 100mg;   - film coated tablet - 100 mg - active: topiramate 100mg   excipient: colloidal silicon dioxide croscarmellose sodium opadry yellow 85g32313 magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 200mg;   - film coated tablet - 200 mg - active: topiramate 200mg   excipient: colloidal silicon dioxide croscarmellose sodium opadry ii pink 85g34776 magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 25mg;   - film coated tablet - 25 mg - active: topiramate 25mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose opadry white 85f18422 pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - topiramate 50mg;   - film coated tablet - 50 mg - active: topiramate 50mg   excipient: colloidal silicon dioxide croscarmellose sodium opadry yellow 85g32312 magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch - topiramate actavis is indicated in adults and children. topiramate actavis tablet range is not suitable for any children weighing less than 25 kg and is not suitable as monotherapy for children or adolescents weighing less than 50 kg. - as monotherapy in patients with newly diagnosed epilepsy - for conversion to monotherapy in patients with epilepsy - as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 100 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; sodium starch glycollate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

proficient rx lp - topiramate (unii: 0h73wjj391) (topiramate - unii:0h73wjj391) - topiramate tablets usp are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic seizures. safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see clinical studies (14.1)] .                                                                  topiramate tablets usp are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with lennox-gastaut syndrome [see clinical studies (14.2)] . none pregnancy category d  [see  warnings and precautions 5.7 ] topiramate tablets can cause fetal harm when administered to a pregnant woman. data from pregnancy registries indicate that infants exposed to topiramate in utero have an increased risk for cleft lip and/or cleft

ארצות הברית - אנגלית - NLM (National Library of Medicine)

proficient rx lp - topiramate (unii: 0h73wjj391) (topiramate - unii:0h73wjj391) - topiramate tablets usp are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic seizures. safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see clinical studies (14.1)] .                                                                  topiramate tablets usp are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with lennox-gastaut syndrome [see clinical studies (14.2)] . none pregnancy category d  [see  warnings and precautions 5.7 ] topiramate tablets can cause fetal harm when administered to a pregnant woman. data from pregnancy registries indicate that infants exposed to topiramate in utero have an increased risk for cleft lip and/or cleft